Corbus Pharmaceuticals "CRBP" - (1)
Updated: Jun 7, 2020
Investing in biotech companies have suddenly become a hot topic among investors as the world is fighting to develop a vaccine to curb the spread of Covid-19. Many investors are chasing after small biotech companies that are promising to successfully develop a vaccine for the novel coronavirus, resulting in a secular decline in the share price of other pharmaceutical companies that are on the brink of making history by obtaining the approval of the Federal Drug and Food Administration (FDA) to commercialize their products. Corbus Pharmaceuticals Holdings, Inc. (CRBP) is one such biotech company that is not receiving the attention it deserves from investors.
Corbus Pharmaceuticals Holdings is a late-stage biotech company with a focus on developing various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company has products in both the clinical trial phase and the pre-clinical stage:
Lenabasum. In Phase 3 trial for the treatment of systemic sclerosis and dermatomyositis and in Phase 2 trial to treat systemic lupus erythematosus and cystic fibrosis.
CRB-4001. Preclinical stage to treat liver, lung, heart, and kidney fibrotic diseases
The company has unveiled a three-tier business strategy to navigate the pre-clinical stage and be ready for the commercialization of its products.
Corbus could become the first company to commercialize a treatment for systemic sclerosis
If investors are not sure about what systemic sclerosis is, it is an autoimmune rheumatic disease characterized by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. This disease can be life-threatening, and despite the immense technological and biological progress made in the last couple of decades, systemic sclerosis remains a condition to which treatment is yet to be discovered.
As is often the case with these types of diseases and conditions, the very first company to make a breakthrough discovery is poised to generate substantial financial gains. Corbus is in a strong position to become that company when it comes to treating systemic sclerosis as the company is the only biotech company with a late-stage experimental drug.
The Phase 2 trials have already delivered attractive results for the use of lenabasum to treat this disease. The ACR CRISS score (Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis) is a widely used barometer to gauge a measure of the success of clinical trials aimed at treating this disease. Even though pharmaceutical giants such as Roche and Bristol-Myers Squibb are also in the race to develop a treatment for this condition, little-known Corbus is showing better results. For instance, the median ACR combined response index in diffuse cutaneous systemic sclerosis score remained at or above 0.95 out of the maximum score of 1.
Source: Investor presentation
The company is showing promising signs in its trials for dermatomyositis and cystic fibrosis as well, which improves the prospects of the company as its future does not depend on the success of just one product.